EUCTR2016-003064-38-GB进行中（未招募）1 期
An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer - Preoperative Radiotherapy And E7046 in Rectum Cancer (PRAER 1)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Diagnosis of histologically confirmed invasive primary rectal carcinoma
- •2.Age =18 years at the time of informed consent
- •3.Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •4.Subjects must have locally advanced rectum cancer where primary resection without CRT is unlikely to achieve clear margins as defined by MRI, with no metastatic disease, as assessed by local review.
- •5.Disease which can be encompassed within a radical radiotherapy treatment volume
- •6.Subject must consent to repeated biopsy as detailed in Table 5 (Section 9.4.2.1) to allow the acquisition of fresh and/or formalin-fixed paraffin-embedded (FFPE) material. Available archived tumor material may be submitted as the pretreatment biopsy provided that minimum requirements are met by local pathology review as defined in the laboratory manual. If archived tumor material is not available or does not meet minimum requirements then a fresh tumor biopsy must be obtained in accordance with local institutional practice.
- •7.Adequate renal function defined as serum creatinine <1.5 × upper limit of normal (ULN) (or use SI units or calculated creatinine clearance =50 mL/min per the Cockcroft and Gault formula [Appendix 1]).
- •8.Adequate bone marrow function:
- •a.Absolute neutrophil count (ANC) = 1500/mm3 (= 1.5 × 103/µL)
- •b.Platelets = 100,000/mm3 (= 100 × 109/L)
- •c.Hemoglobin = 9.0 g/dL
- •9.Adequate liver function:
- •a.Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) = 1.5.
- •b.Total bilirubin = 1.5 × ULN except for unconjugated hyperbilirubinemia or Gilbert’s syndrome.
- •c.Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) = 2.5 × ULN.
- •10.No prior pelvic radiotherapy, chemotherapy, immunotherapy or other anti-cancer treatment for rectal cancer
- •11.No prior exposure to CSF1R antagonists such as but not limited to emactuzumab (RG7155) (Roche), PLX3397 (Plexicon), JNJ40346627 (J & J), including both anti-CSF1R and small molecule inhibitors and EP4 antagonists.
- •12.No preexisting condition which would deter radiotherapy, eg, fistulas, severe ulcerative colitis (particularly subjects currently taking sulphasalazine), Crohn’s disease, prior adhesions.
- •13.Willing and able to give informed consent and comply with all aspects of the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 23
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 12
排除标准
- •1.Any contraindications to MRI.
- •2.Unfit to receive study treatment or subsequent surgical resection.
- •3.Active hydronephrosis.
- •4.Unequivocal evidence of metastatic disease defined by CT (includes resectable metastases).
- •5.Prolongation of corrected QT (QTc) interval to >480 msec when electrolyte balance is normal.
- •6.Recent occurrence (within 3-6 months) of a major thromboembolic event.
- •7.Subjects receiving oral warfarin are not eligible for this study.
- •8.Previous radiotherapy in the pelvic region.
- •9.Cardiac conditions.
- •10.Has a known additional malignancy that is progressing and/or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, previous ductal carcinoma in situ (DCIS), or breast cancer diagnosed more than 5 years ago, as long as adequately treated or in situ, or early (up to stage 1B1) cervical cancer, or vulval intraepithelial neoplasia (VIN), or vulval cancer adequately treated without pelvic RT
- •11.Refractory nausea and vomiting, chronic gastrointestinal diseases (eg, inflammatory bowel disease), or significant bowel resection that may impair adequate absorption and bioavailability of study drug. Major disturbance of bowel function (eg, gross fecal incontinence or requiring > 6 mg loperamide each day).
- •12.Subjects with prior Hepatitis B or C infection with inadequate liver function (adequate liver function as defined in inclusion Criterion # 9)
- •13.Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access and defunctioning stoma or any other surgical procedures not considered major by the investigator) which would prevent administration of study treatment.
- •14.Known dihydropyrimidine dehydrogenase (DPD) deficiency.
- •15.Subjects with progressive neurological dysfunction that would confound the evaluation of neurological and other toxicities; any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any subject with known active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.
- •16.Subjects with interstitial pneumonia or extensive and symptomatic fibrosis of the lungs
- •17.Subjects with any active autoimmune disease or a documented history of autoimmune disease, poorly controlled asthma or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo or resolved childhood asthma/atopy. Subjects with asthma who require intermittent use of bronchodilators (such as albuterol) will not be excluded from this study.
- •18.Any other major illness that, in the investigator’s judgment, will substantially increase the risk associated with the subject’s participation in this study
- •19.Has received a live vaccine within 30 days of planned start of study therapy.
- •20.Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin [ß-hCG] test with a minimum sensitivity of 25 IU/L or equivalent units of ß-hCG). A separate baseline
研究者
相似试验
进行中（未招募）
1 期
A trial to investigate the safety and tolerability of E7046 when it is given together with radiation and chemotherapy before surgery in patients who have rectum cancer.ocally advanced rectum cancerMedDRA version: 20.0Level: LLTClassification code 10007464Term: Carcinoma rectumSystem Organ Class: 100000004864EUCTR2016-003064-38-PLAdlai Nortye USA INC.35
进行中（未招募）
1 期
An early phase trial studying how well E7080 works in treating patients with advanced kidney cancer which has spread to other parts of the body. The first part of the trial will study the combination of E7080 and everolimus. The second part will compare the treatments when given alone and when given in combination. The trial is taking place worldwide, patients know if they are receiving the study drug alone, in combination with everolimus or if they are recieving everolimus alone.nresectable Advanced or Metastatic Renal Cell CarcinomaMedDRA version: 18.0Level: PTClassification code 10038414Term: Renal cell carcinoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019484-10-PLEisai Ltd150
进行中（未招募）
1 期
An early phase trial studying how well E7080 works in treating patients with advanced kidney cancer which has spread to other parts of the body. The first part of the trial will study the combination of E7080 and everolimus. The second part will compare the treatments when given alone and when given in combination. The trial is taking place worldwide, patients know if they are receiving the study drug alone, in combination with everolimus or if they are recieving everolimus alone.EUCTR2010-019484-10-ESEisai Ltd178
进行中（未招募）
1 期
An early phase trial studying how well E7080 works in treating patients with advanced kidney cancer which has spread to other parts of the body. The first part of the trial will study the combination of E7080 and everolimus. The second part will compare the treatments when given alone and when given in combination. The trial is taking place worldwide, patients know if they are receiving the study drug alone, in combination with everolimus or if they are recieving everolimus alone.nresectable Advanced or Metastatic Renal Cell CarcinomaMedDRA version: 20.0Level: PTClassification code 10038414Term: Renal cell carcinoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019484-10-CZEisai Ltd150
进行中（未招募）
1 期
An early phase trial studying how well E7080 works in treating patients with advanced kidney cancer which has spread to other parts of the body. The first part of the trial will study the combination of E7080 and everolimus. The second part will compare the treatments when given alone and when given in combination. The trial is taking place worldwide, patients know if they are receiving the study drug alone, in combination with everolimus or if they are recieving everolimus alone.EUCTR2010-019484-10-GBEisai Ltd150